ClinicalTrials.gg
CompletedNCT07622004Updated Jun 3, 2026

Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.

A Phase 3 interventional study of Botulinum Toxin Type A Injection [INI101] and Botulinum Toxin Type A Injection [Botox] in Glabellar Lines, sponsored by INIBIO Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by INIBIO Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 11 months after the study started (first participant enrolled May 2021, registered May 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
292
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX® in subjects with moderate to severe glabellar lines.

02

Conditions studied

  • Glabellar Lines
03

In context

Lead sponsor

This is the only study on the registry with INIBIO Co., Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male or female participants aged between 19 and 65 years old.
  2. Participants whose glabellar line score was 2 (moderate) or higher of glabellar line score at maximum frown based on the investigator's judgment at screening and randomization.
  3. Participants who voluntarily gave a consent in writing to participate in the clinical study with full knowledge of details of the study after listening to them.
  4. Participants who can understand and comply with the procedures and visit schedules of the study.

Exclusion criteria

Exclusion Criteria:

  1. Systemic neuromuscular junction disorders (e.g., myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, hereditary motor neuropathy, etc.)
  2. History of blepharoplegia or ptosis
  3. Prominent facial asymmetry
  4. Glabellar lines that are physically difficult to be improved, such as the case where the lines are not removed by hands
  5. Participants who have received any drugs that can act as a systemic muscle relaxant within 4 weeks prior to screening
  6. Participants who have received anticoagulants, anti- agents, or systemic NSAIDs within 7 days prior to administration of products (however, low-dose aspirin [325 mg/day or less] administered for antithrombotic purposes is acceptable)
  7. Participants who have participated in other clinical trials of a drug/medical device within 30 days from participating in this clinical study and have been administered/treated with the investigational product/medical device
  8. Participants deemed ineligible for this study for other reasons based on the investigator's judgment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
292 participants (actual)

Study arms

  • Experimental
    Botulinum toxin type A (INI101)

    Drug: Botulinum Toxin Type A Injection [INI101]

  • Active comparator
    Botulinum toxin type A (BOTOX®)

    Drug: Botulinum Toxin Type A Injection [Botox]

Interventions

06

What researchers measure

Primary outcomes

  1. Improvement rate of glabellar lines at maximum frown according to the investigator's on-site assessment

    Investigator assessed the subject's glabellar lines 'At maximum frown' on a 4-point facial wrinkle scale (FWS) after 4 weeks of the administration of the investigational product compared to baseline, based on the Photo Guidelines for Glabellar Line Evaluation.

    Time frame: Baseline to week 4

Secondary outcomes

  1. Improvement rate of glabellar lines at maximum frown according to the investigator's on-site assessment

    Investigator assessed the subject's glabellar lines 'At maximum frown' on a 4-point facial wrinkle scale (FWS) at each time point after the administration of the investigational product compared to baseline, based on the Photo Guidelines for Glabellar Line Evaluation.

    Time frame: Baseline to week 8, 12, 16

  2. Improvement rate of glabellar lines at rest according to the investigator's on-site assessment

    Investigator performed on-site assessment of the subject's glabellar lines 'At rest' on a 4-point facial wrinkle scale (FWS) at each time point after the administration of the investigational product compared to baseline, based on the Photo Guidelines for Glabellar Line Evaluation.

    Time frame: Baseline to week 4, 8, 12, 16

  3. Improvement rate of glabellar lines at maximum frown according to the independent assessor's photo assessment

    Independent assessor assessed the subject's glabellar lines 'At maximum frown' ' on a 4-point facial wrinkle scale (FWS) at each time point after the administration of the investigational product compared to baseline, based on the Photo Guidelines for Glabellar Line Evaluation. An independent assessor separately conducted the FWS assessment subsequently based on the photographs taken.

    Time frame: Baseline to week 4, 8, 12, 16

  4. Improvement rate of glabellar lines at rest according to the independent assessor's photo assessment

    Independent assessor assessed the subject's glabellar lines 'At rest' on a 4-point facial wrinkle scale (FWS) at each time point after the administration of the investigational product compared to baseline, based on the Photo Guidelines for Glabellar Line Evaluation. An independent assessor separately conducted the FWS assessment subsequently based on the photographs taken.

    Time frame: Baseline to week 4, 8, 12, 16

  5. Improvement rate of glabellar lines as assessed by the subject

    Subjects assessed their glabellar lines at each time point after the administration of the investigational product compared to baseline.

    Time frame: Baseline to week 4, 8, 12, 16

  6. Subject's satisfaction

    Subject's satisfaction score for the improvement of glabellar lines was investigated at each time point after the administration of the investigational product compared to before administration.

    Time frame: Baseline to week 4, 8, 12, 16

07

Study locations

1 site
  • INIBIO Co., Ltd.
    Seoul, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Jan 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 2, 2026
StartActual
May 27, 2021
Primary completionActual
Jan 30, 2022
CompletionActual
Mar 5, 2022
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07622004
Lead sponsor
INIBIO Co., Ltd.
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
May 27, 2021
Primary completion
Jan 30, 2022
Completion
Mar 5, 2022
Last update
Jun 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion